Interleukin 33/ST2 Axis Components Are Associated to Desmoplasia, a Metastasis-Related Factor in Colorectal Cancer.
Adult
Aged
Cancer-Associated Fibroblasts
/ metabolism
Cell Movement
/ physiology
Cell Proliferation
/ physiology
Colorectal Neoplasms
/ metabolism
Female
Humans
Interleukin-1 Receptor-Like 1 Protein
/ metabolism
Interleukin-33
/ metabolism
Male
Middle Aged
Neoplasm Invasiveness
/ pathology
Tumor Microenvironment
/ physiology
cancer associated fibroblasts
colorectal cancer
desmoplasia
epithelial-mesenchymal transition
interleukin 33
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2019
2019
Historique:
received:
22
09
2018
accepted:
03
06
2019
entrez:
9
7
2019
pubmed:
10
7
2019
medline:
21
10
2020
Statut:
epublish
Résumé
In colorectal cancer (CRC), cancer-associated fibroblasts (CAFs) are the most abundant component from the tumor microenvironment (TM). CAFs facilitate tumor progression by inducing angiogenesis, immune suppression and invasion, thus altering the organization/composition of the extracellular matrix (i.e., desmoplasia) and/or activating epithelial-mesenchymal transition (EMT). Soluble factors from the TM can also contribute to cell invasion through secretion of cytokines and recently, IL-33/ST2 pathway has gained huge interest as a protumor alarmin, promoting progression to metastasis by inducing changes in TM. Hence, we analyzed IL-33 and ST2 content in tumor and healthy tissue lysates and plasma from CRC patients. Tissue localization and distribution of these molecules was evaluated by immunohistochemistry (using localization reference markers α-smooth muscle actin or α-SMA and E-cadherin), and clinical/histopathological information was obtained from CRC patients.
Identifiants
pubmed: 31281317
doi: 10.3389/fimmu.2019.01394
pmc: PMC6598075
doi:
Substances chimiques
IL1RL1 protein, human
0
IL33 protein, human
0
Interleukin-1 Receptor-Like 1 Protein
0
Interleukin-33
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1394Commentaires et corrections
Type : ErratumIn
Références
J Clin Pathol. 2005 Jan;58(1):32-8
pubmed: 15623479
Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):419-24
pubmed: 15623559
Immunity. 2005 Nov;23(5):479-90
pubmed: 16286016
Clin Cancer Res. 2007 Apr 1;13(7):2082-90
pubmed: 17404090
Oncogene. 2008 Oct 6;27(45):5904-12
pubmed: 18836471
PLoS One. 2008 Oct 06;3(10):e3331
pubmed: 18836528
Biochem Biophys Res Commun. 2009 Jun 19;384(1):105-9
pubmed: 19393621
PLoS One. 2009 Nov 23;4(11):e7965
pubmed: 19956757
Inflamm Bowel Dis. 2010 Jul;16(7):1097-107
pubmed: 20014018
Nature. 2010 Apr 29;464(7293):1367-70
pubmed: 20200518
Exp Cell Res. 2010 May 1;316(8):1324-31
pubmed: 20211171
Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6430-5
pubmed: 20308560
J Immunol. 2010 Sep 15;185(6):3472-80
pubmed: 20693421
Oncotarget. 2012 Mar;3(3):267-85
pubmed: 22408128
Cancer Res. 2012 May 15;72(10):2473-80
pubmed: 22414581
Colorectal Dis. 2013 Jan;15(1):47-51
pubmed: 22642835
Cytokine. 2012 Nov;60(2):514-21
pubmed: 22819319
Cancer Sci. 2013 Apr;104(4):437-44
pubmed: 23298232
Cancer Lett. 2013 Jul 28;335(2):463-71
pubmed: 23499895
Oncogene. 2014 May 8;33(19):2423-31
pubmed: 23728338
Front Oncol. 2013 May 21;3:130
pubmed: 23734346
J Pathol. 2013 Oct;231(2):180-9
pubmed: 23775566
Clin Cancer Res. 2013 Nov 1;19(21):5914-26
pubmed: 24052018
Int J Cancer. 2014 Apr 1;134(7):1669-82
pubmed: 24105680
Oncoimmunology. 2013 Sep 1;2(9):e25563
pubmed: 24319632
Cancer Res. 2014 Mar 15;74(6):1789-800
pubmed: 24448242
Physiol Genomics. 2014 Apr 1;46(7):223-44
pubmed: 24520152
Front Immunol. 2014 Apr 07;5:141
pubmed: 24778632
Asian Pac J Cancer Prev. 2014;15(8):3503-5
pubmed: 24870747
J Immunol Res. 2014;2014:149185
pubmed: 24901008
Br J Cancer. 2014 Nov 25;111(11):2082-90
pubmed: 25247323
Biochem Biophys Res Commun. 2014 Oct 24;453(3):486-92
pubmed: 25280997
Cancer Immunol Immunother. 2015 Feb;64(2):181-90
pubmed: 25324197
Ann Surg Oncol. 2015 May;22(5):1504-12
pubmed: 25395146
Eur J Surg Oncol. 2015 Mar;41(3):300-8
pubmed: 25468456
BMC Cancer. 2015 Jan 21;15:14
pubmed: 25603809
Int J Cancer. 2016 Jan 1;138(1):22-9
pubmed: 25604320
Immunol Lett. 2015 Mar;164(1):11-7
pubmed: 25662624
Trends Biotechnol. 2015 Apr;33(4):230-6
pubmed: 25708906
Proc Natl Acad Sci U S A. 2015 May 12;112(19):E2487-96
pubmed: 25918379
Int J Radiat Oncol Biol Phys. 2015 Oct 1;93(2):425-35
pubmed: 26253394
Cytokine Growth Factor Rev. 2015 Dec;26(6):615-23
pubmed: 26271893
Nat Rev Immunol. 2015 Nov;15(11):669-82
pubmed: 26471778
Br J Cancer. 2016 Jan 12;114(1):37-43
pubmed: 26679377
Oncoimmunology. 2015 Jun 26;5(1):e1062966
pubmed: 26942077
Mol Carcinog. 2017 Jan;56(1):272-287
pubmed: 27120577
J Clin Med. 2016 Apr 29;5(5):null
pubmed: 27136592
Nat Rev Dis Primers. 2015 Nov 05;1:15065
pubmed: 27189416
Br J Pharmacol. 2016 Aug;173(16):2532-42
pubmed: 27300306
JAMA Oncol. 2017 Feb 1;3(2):211-219
pubmed: 27787550
Trends Immunol. 2017 Jan;38(1):29-38
pubmed: 27810463
Hum Pathol. 2017 Feb;60:151-159
pubmed: 27836787
Nat Commun. 2016 Nov 24;7:13589
pubmed: 27882929
Front Immunol. 2017 Jan 09;7:682
pubmed: 28119694
Cancer Res. 2017 May 15;77(10):2735-2745
pubmed: 28249897
J Natl Compr Canc Netw. 2017 Mar;15(3):411-419
pubmed: 28275039
Front Immunol. 2017 Apr 24;8:475
pubmed: 28484466
Trends Cancer. 2016 Mar;2(3):111-113
pubmed: 28741529
Am J Surg Pathol. 2017 Nov;41(11):1506-1512
pubmed: 28877064
Cell Immunol. 2019 Sep;343:103740
pubmed: 29329638
Technol Cancer Res Treat. 2018 Jan 1;17:1533033818780091
pubmed: 29950152
Int J Mol Sci. 2018 Sep 09;19(9):null
pubmed: 30205617
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
JCI Insight. 2018 Oct 18;3(20):
pubmed: 30333314
Front Immunol. 2018 Oct 26;9:2506
pubmed: 30416507
Front Oncol. 2018 Nov 28;8:561
pubmed: 30547011
Front Immunol. 2018 Dec 20;9:3051
pubmed: 30619376
Proc Natl Acad Sci U S A. 2019 Feb 12;116(7):2646-2651
pubmed: 30696763
Nat Rev Gastroenterol Hepatol. 2019 May;16(5):282-295
pubmed: 30778141